Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
mTORC2 regulates renal tubule sodium uptake by promoting ENaC activity
Catherine E. Gleason, … , Lawrence G. Palmer, David Pearce
Catherine E. Gleason, … , Lawrence G. Palmer, David Pearce
Published November 21, 2014
Citation Information: J Clin Invest. 2015;125(1):117-128. https://doi.org/10.1172/JCI73935.
View: Text | PDF
Research Article Nephrology Article has an altmetric score of 4

mTORC2 regulates renal tubule sodium uptake by promoting ENaC activity

  • Text
  • PDF
Abstract

The epithelial Na+ channel (ENaC) is essential for Na+ homeostasis, and dysregulation of this channel underlies many forms of hypertension. Recent studies suggest that mTOR regulates phosphorylation and activation of serum/glucocorticoid regulated kinase 1 (SGK1), which is known to inhibit ENaC internalization and degradation; however, it is not clear whether mTOR contributes to the regulation of renal tubule ion transport. Here, we evaluated the effect of selective mTOR inhibitors on kidney tubule Na+ and K+ transport in WT and Sgk1–/– mice, as well as in isolated collecting tubules. We found that 2 structurally distinct competitive inhibitors (PP242 and AZD8055), both of which prevent all mTOR-dependent phosphorylation, including that of SGK1, caused substantial natriuresis, but not kaliuresis, in WT mice, which indicates that mTOR preferentially influences ENaC function. PP242 also substantially inhibited Na+ currents in isolated perfused cortical collecting tubules. Accordingly, patch clamp studies on cortical tubule apical membranes revealed that mTOR inhibition markedly reduces ENaC activity, but does not alter activity of K+ inwardly rectifying channels (ROMK channels). Together, these results demonstrate that mTOR regulates kidney tubule ion handling and suggest that mTOR regulates Na+ homeostasis through SGK1-dependent modulation of ENaC activity.

Authors

Catherine E. Gleason, Gustavo Frindt, Chih-Jen Cheng, Michael Ng, Atif Kidwai, Priyanka Rashmi, Florian Lang, Michel Baum, Lawrence G. Palmer, David Pearce

×

Figure 1

mTOR is required for Na+ retention in vivo.

Options: View larger image (or click on image) Download as PowerPoint
mTOR is required for Na+ retention in vivo.
WT mice were treated with (A...
WT mice were treated with (A–E) the catalytic site mTOR inhibitor PP242 (30 mg/kg i.p., n = 6 mice per treatment group) or (F–J) the mTORC1 inhibitor rapamycin (1.5 mg/kg i.p., n = 6 mice per treatment group), and urine was collected for 6 hours using balance cages (see Methods). Values for (A and F) urine volume, (B and G) net Na+ excretion (calculated as urinary Na+ × volume [mmol/6 h]), (C and H) net K+ excretion (urinary K+ × vol), (D and I) net Cl– excretion (urinary Cl– × vol), and (E and J) urinary Na+/K+ concentration ratio represent fold change relative to the vehicle-treated group. Data represent mean ± SEM; differences were determined by unpaired Student’s t test. *P < 0.05 vs. vehicle.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Posted by 6 X users
On 1 Facebook pages
46 readers on Mendeley
See more details